Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022

Rhea-AI Summary

Precision BioSciences, Inc. (Nasdaq: DTIL) will publish its financial results for Q4 and fiscal year 2021 on March 15, 2022, alongside a business update. The company focuses on developing ARCUS®-based ex vivo CAR T and in vivo gene editing therapies aimed at treating genetic and infectious diseases lacking adequate treatments. With its proprietary ARCUS platform, Precision BioSciences aims for therapeutic safety and control.

Positive

• ARCUS® platform designed for therapeutic safety and control.
• Pipeline includes multiple 'off-the-shelf' CAR T immunotherapy candidates.

Negative

• None.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS^®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2021 and provide a business update on March 15, 2022.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS^® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005213/en/

Investor Contact:

Alex Kelly

Chief Financial Officer

Alex.Kelly@precisionbiosciences.com

Media Contact:

Maurissa Messier

Senior Director, Corporate Communications

Maurissa.Messier@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

When will Precision BioSciences release its Q4 and fiscal year 2021 financial results?

Precision BioSciences plans to publish its financial results on March 15, 2022.

What is the focus of Precision BioSciences' clinical pipeline?

The pipeline focuses on developing gene editing therapies and CAR T immunotherapy candidates.

What technology does Precision BioSciences use for gene editing?

Precision BioSciences employs the ARCUS® genome editing platform.